Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Shi, Anhui ^a   Zhu, Guangying ^a   Wu, Hao ^a   Yu, Rong ^a   Li, Fuhai ^a   Xu, Bo ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DOSIMETRY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION RESPONSE; ACUTE DISEASE; DRUG EFFECT; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIATION PNEUMONITIS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 77952001776     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-35     Document Type: Article

References (36)

1. Liandi L, Keqin Y, Siwei Z, Fengzhu L, Xiaonong Z. Statistical Analysis of Data from 12 Cancer Registries in China. Bull Chin Cancer 2002, 11:497-507.
2. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
3. Komaki R, Seiferheld W, Curran W, Langer C, Lee J, Hauser S, Movasas B, Wasserman T, Russell A, Byhardt R. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410) [Abstract]. Int J Radiat Oncol Biol Phys 2000, 48:113.
4. Curran W, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wasserman T, Sause W, Cox J. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III Nsclc: RTOG 9410. Am Soc Clin Oncol 2003, 22. abstr 2499.
5. Kirkbride P, Hatton M, Lorigan P, Joyce P, Fisher P. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol 2002, 14:361-366.
6. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications: Preliminary results. Strahlenther Onkol 2003, 179(12):823-831. 10.1007/s00066-003-1127-8, 14652671.
7. Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001, 51:650-659.
8. Graham MV. Predicting radiation response. Int J Radiat Oncol Biol phys 1997, 39:561-562.
9. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spahn U, Graham MV, Drzymala RE, Purdy JA, Lichter AS, Martel MK, Ten Haken RK. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998, 42:1-9.
10. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002, 54:329-339. 10.1016/S0360-3016(02)02929-2, 12243805.
11. Kim TH, Cho KH, Pyo HR, Lee JS, Zo JI, Lee DH, Lee JM, Kim HY, Hwangbo B, Park SY, Kim JY, Shin KH, Kim DY. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005, 235:208-215. 10.1148/radiol.2351040248, 15703313.
12. Marks LB, Munley MT, Bentel GC, Zhou SM, Hollis D, Scarfone C, Sibley GS, Kong FM, Jirtle R, Jaszczak R, Coleman RE, Tapson V, Anscher M. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 1997, 39:563-570.
13. Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, Kutcher G, Harrison L, Hahn C, Ginsberg R, Rusch V, Kris M, Fuks Z. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997, 44:17-22. 10.1016/S0167-8140(97)01907-5, 9288852.
14. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-329.
15. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T, Takada Y. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2003, 55:110-115. 10.1016/S0360-3016(02)03807-5, 12504042.
16. Chang DT, Olivier KR, Morris CG, Liu C, Dempsey JF, Benda RK, Palta JR. The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis. Int J Radiat Oncol Biol Phys 2006, 65:125-131.
17. Armstrong JG, Zelefsky MJ, Leibel SA, Burman C, Han C, Harrison LB, Kutcher GJ, Fuks ZY. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol 1995, 6:693-697.
18. Marks LB, Spencer DP, Sherouse GW, Bentel G, Clough R, Vann K, Jaszczak R, Coleman RE, Prosnitz LR. The role of three dimensional functional lung in radiation treatment planning: the functional dose volume histogram. Int J Radiat Oncol Biol phys 1995, 33:65-75.
19. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki R. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3-DCRT). Int J Radiat Oncol Biol Phys 2006, 66:1399-1407.
20. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1258-1267.
21. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:94-102.
22. International Commission on Radiation Units and Measurements ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. 1993, Bethesda; International Commission on Radiation Units and Measurements, International Commission on Radiation Units and Measurements.
23. International Commission on Radiation Units and Measurements ICRU Report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report 50). 1999, Bethesda; International Commission on Radiation Units and Measurements, International Commission on Radiation Units and Measurements.
24. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181. 10.1016/S1053-4296(03)00031-6, 12903007.
25. Kwa SL, Theuws JC, Wagenaar A, Damen EM, Boersma LJ, Baas P, Muller SH, Lebesque JV. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 1998, 48:61-69. 10.1016/S0167-8140(98)00020-6, 9756173.
26. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. Factor predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000, 48:89-94. 10.1016/S0360-3016(00)00648-9, 10924976.
27. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998, 34:71-75. 10.1016/S0959-8049(97)00377-8, 9624240.
28. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998, 42(3):469-78.
29. Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis. Radiother Oncol 2004, 71:175-181. 10.1016/j.radonc.2004.02.005, 15110451.
30. Quon H, Shepherd FA, Payne DG, Coy P, Murray N, Feld R, Pater J, Sadura A, Zee B. The influence of age on the delivery, tolerance, an efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999, 43:39-45.
31. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother Oncol 2003, 67:275-283. 10.1016/S0167-8140(03)00119-1, 12865175.
32. Willner J, Jost A, Baier K, Flentje M. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 2003, 179:548-556. 10.1007/s00066-003-1078-0, 14509954.
33. Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005, 61:1355-1363.
34. Zhu X, Wang L, Ou G, Wang Y, Zhang H, Chen D, Feng Q, Dai J, Zhang Z, Yin W. Risk Factors for Severe Acute Radiation Pneumonitis In Stage III Non-Small-Cell Lung Cancer Treated With 3D-CRT [Abstract]. Int J Radiat Oncol Biol Phys 2006, 66:S466.
35. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 2007, 67:410-6.
36. Gopal R, Tucker SL, Komaki R, Liao Z, Forster KM, Stevens C, Kelly JF, Starkschall G. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 2003, 56:106-113.